IRIS
CARLOMAGNO, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.927
EU - Europa 1.378
AS - Asia 409
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
SA - Sud America 1
Totale 3.758
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.885
IT - Italia 572
CN - Cina 364
NL - Olanda 251
IE - Irlanda 154
FI - Finlandia 122
UA - Ucraina 108
SE - Svezia 57
DE - Germania 51
CI - Costa d'Avorio 39
CA - Canada 36
GB - Regno Unito 30
FR - Francia 22
IN - India 18
VN - Vietnam 10
IR - Iran 7
BE - Belgio 6
MX - Messico 4
EU - Europa 3
HK - Hong Kong 3
JP - Giappone 2
SG - Singapore 2
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EE - Estonia 1
KR - Corea 1
NO - Norvegia 1
PK - Pakistan 1
PR - Porto Rico 1
PT - Portogallo 1
TR - Turchia 1
Totale 3.758
Salva come PNG Salva come JPEG
Città #
Chandler 335
Amsterdam 248
Millbury 171
Ashburn 141
Princeton 128
Napoli 120
Beijing 111
Nanjing 100
Jacksonville 76
Naples 59
Wilmington 59
Boston 53
Nanchang 44
Des Moines 41
Ottawa 34
Tianjin 23
Jiaxing 21
Houston 18
Shenyang 18
Washington 17
Ann Arbor 15
Lawrence 15
Woodbridge 14
Hebei 13
Milan 13
Norwalk 12
Falls Church 10
Indiana 10
Kunming 10
Redwood City 10
Lentini 9
Changsha 8
Dong Ket 8
Rome 8
Torre Annunziata 8
Kronberg 7
Boardman 6
Dublin 6
Pune 6
Rozzano 6
New York 5
Castellammare di Stabia 4
Fairfield 4
Menfi 4
Salerno 4
San Mateo 4
Bari 3
Brescia 3
Cambridge 3
Fremont 3
Hong Kong 3
Lanzhou 3
Leawood 3
Menlo Park 3
Mugnano Di Napoli 3
Sciacca 3
Seattle 3
Serravalle Scrivia 3
Shanghai 3
Villaricca 3
Villarosa 3
Acerra 2
Bientina 2
Caserta 2
Castel San Giorgio 2
Castellammare Di Stabia 2
Changchun 2
Courcelles 2
Delhi 2
Edegem 2
Edinburgh 2
Frankfurt am Main 2
Genova 2
Hangzhou 2
Hanoi 2
Hicksville 2
Jersey City 2
Latina 2
Mariano Comense 2
Messina 2
Newbury Park 2
Nola 2
Noventa di Piave 2
Nutley 2
Orange 2
Pachuca 2
Piove Di Sacco 2
Pozzuoli 2
Pregnana Milanese 2
Rapolla 2
Redmond 2
San Francisco 2
San Giorgio A Cremano 2
San Giovanni Rotondo 2
San Giovanni Teatino 2
Sarno 2
Scafati 2
Scilla 2
Suri 2
Torino 2
Totale 2.159
Salva come PNG Salva come JPEG
Nome #
null 223
Manuale di Oncologia Clinica 95
STATO DELL'ARTE SULLA CHEMIOTERAPIA NEL CANCRO DEL COLON 78
null 67
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. 60
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. 57
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. 54
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? 54
Management of patients with BRCA1/2-associated breast cancer 50
Less frequently mutated genes in colorectal cancer: Evidences from next-generation sequencing of 653 routine cases 47
Raltitrexed versus standard leucovorin-modulated 5Fluorouracil: results form the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). 46
A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy 46
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 44
Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. 43
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 42
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients 41
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. 40
UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients 40
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 38
Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer 38
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study. 37
KRAS Mutant Allele Specific Imbalance (MASI) assessment in routine samples of metastatic colorectal cancer patients 37
Bevacizumab as 4th line treatment in metastatic colorectal cancer 36
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 36
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 36
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 35
A predictive index of axillary nodal involvement in operable breast cancer. 35
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. 34
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 33
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 33
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors. 33
Double complete response in MCRC patient 33
Next-generation sequencing in the genomic profiling of synchronous colonic carcinomas: comment on Li et al (2015) 33
Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study 33
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 32
Altri tumori gastrointestinali 32
Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion ofetiopathogenesis and diagnostic tools 32
Risk factors for cancer-related venous thromboembolism in ambulatory patients. 32
Adjuvant treatment for locally advanced rectal cancer patients after pre-operative chemoradiotherapy: when, and for whom? 32
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer 31
Cancro del colon-retto 31
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 31
An unusual case of primary choriocarcinoma of the lung 31
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. 30
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 30
Ovarian metastasis following gallbladder carcinoma: a case report. 30
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 30
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 30
Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report 30
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. 30
Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. 29
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. 29
Basaloid Squamous Cell Carcinoma: A Rare Tumor at the Esophagogastric Junction and an Unexpected Durable Complete Response to FOLFOX-4. 29
MULTIPLE PRIMARY MALIGNANT NEOPLASM AND FAMILIAR ANAMNESIS 28
MicroRNA profiling as predictive factor of complete pathological response to neoadjuvant chemoradiothetapy in patients with locally advanced cancer 28
Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review 28
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. 27
null 27
Core curriculum. Oncologia clinica 27
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. 26
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. 26
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 26
KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs, and beyond 26
Cytological diagnosis of thyroid nodules in Hashimoto thyroiditis in elderly patients 26
Il punto sull’Irinotecan: presente e futuro 25
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 25
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 25
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 25
Correlation between bevacizumab-related hypertension and response in mCRC patients 25
Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients 25
Bevacizumab maintenance in metastatic colorectal cancer: How long? 25
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. 25
DNA-flow cytometry (ploidy and s-phase fraction) as prognostic factor in a retrospective series of 515 primary breast-cancer 25
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 24
Adjuvant chemoendocrine therapy for early breast cancer: is it worthwhile? 24
Bevacizumab-induced hypertension is a predictive marker of response and progression free survival in patients treated for metastatic colorectal cancer 24
Forearm cutaneous metastasis of rectal adenocarcinoma: a case report 24
MULTIDISCIPLINARY APPROACH TO PATIENTS WITH MALIGNANT MELANOMA 23
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience 23
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study 23
Prognostic significance of multifocality in primary breast cancer. 22
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. 22
Multiple treatment lines and prognosis in metastatic colorectal cancer patients 22
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 22
microRNA come parametri predittivi di risposta ai farmaci a bersaglio molecolare specifico nelle neoplasie del colon-retto 21
Unusual case of exacerbation of sub-acute descending necrotizing mediastinitis 21
Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial. 21
Neoadjuvant treatment with capecitabine and oxaliplatin in combination with radiotherapy for rectal cancer patients: a phase II study 20
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. 20
Cancro del colon-retto 20
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer 20
Cancro del colon-retto 19
SANGER SEQUENCING IN ROUTINE KRAS TESTING: AREVIEW OF 1720 CASES FROM A PATHOLOGIST’SPERSPECTIVE 19
KRAS mutation detection by high resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer 19
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic coloectal cancer (MCRC): results of the phase III tandomized TRIBE trial 19
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 19
null 18
Skin lesions: unusual presentation of gastric cancer 18
Core curriculum. Oncologia clinica 18
Surgery in lung cancer metastasis 17
Totale 3.350
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.071
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201926 0 0 0 0 0 0 0 0 0 10 9 7
2019/2020452 204 7 17 3 20 7 6 12 2 50 71 53
2020/2021379 12 17 37 26 37 71 23 25 56 27 29 19
2021/2022840 14 3 5 7 1 26 7 43 165 78 165 326
2022/20231.023 147 60 27 50 97 90 6 90 158 242 40 16
2023/2024458 29 93 79 60 29 77 11 75 4 1 0 0
Totale 3.921